Walgreens offloads more Cencora shares
The sale netted about $300 million for Walgreens and shrinks the company’s stake in Cencora to approximately 6%, down from 10%.
Uncategorized
Alphabet’s Verily to sell stop-loss insurance unit to Elevance
The deal could signal that Elevance wants to build out its commercial products to hedge against volatility in Medicaid and privatized Medicare plans.
Alphabet’s Verily to sell stop-loss insurance unit to Elevance Read More »
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s blockbuster Hemlibra.
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial Read More »
Thermo Fisher lays off another 300 workers in Massachusetts
Job cuts in Cambridge and Plainville are the second workforce reduction planned for the facilities in the past three months.
Thermo Fisher lays off another 300 workers in Massachusetts Read More »
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for non-opioid pain treatments that could help quell the still raging opioid epidemic.
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment Read More »
GoodRx names new CFO
Christopher McGinnis is taking the reins as finance chief weeks after the prescription price transparency company also appointed a new CEO.
As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals
Leqembi’s sales in the U.S. continue to underwhelm, overshadowed by its growth by international markets.
As US Sales of Leqembi Lag, Eisai Eyes SubQ Approvals Read More »
Nasdaq Neophytes Acelyrin, Alumis Merge to Tackle Immune-Mediated Diseases
Alumis held its initial public offering in June last year, while Acelyrin debuted on the Nasdaq in mid-2023.
Nasdaq Neophytes Acelyrin, Alumis Merge to Tackle Immune-Mediated Diseases Read More »
After Unforced Error, Novo Execs Try to Boost CagriSema Sentiment—Without Hard Numbers
Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, executives are taking another look at the data but steering clear of making hard bets.
After Unforced Error, Novo Execs Try to Boost CagriSema Sentiment—Without Hard Numbers Read More »
El papel del análisis de datos y la inteligencia artificial en la predicción del rendimiento deportivo
El deporte ha evolucionado con el uso de la tecnología. Ahora, el análisis de datos es crucial. Muchas plataformas ofrecen apuestas La Liga basadas en estadísticas. Esto ayuda a los apostadores a tomar decisiones informadas. Además, los equipos y entrenadores ut …